CEO & Co-Founder
Oriana has global experience creating and leading teams and organizations resulting in successful strategic exits. She brings a wealth of knowledge and expertise from women's health startups and large life science companies, and a passion for entrepreneurship and solving problems that disproportionality affect women. Recognized for her inspirational leadership, Oriana is known for developing a highly productive culture and turning visions into reality.
Alongside her leadership qualities, Oriana has a proven technical record of creating market entry strategies and product launches in new markets alongside driving market share growth in existing diagnostic assay and instrument markets.
Oriana is responsible for building and leading the AOA team, fundraising and developing and executing long-term strategies.
Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.
COO & Co-Founder
Alex is a passionate and dedicated business leader with a track record of launching UK medical device and diagnostics sales companies. He has extensive experience priming markets, launching products and driving early product sales.
In most recent roles, Alex has been committed to commercializing and launching innovative, disruptive products through his own businesses across European healthcare markets with a primary focus on obstetrics and gynecology.
Alex works closely with Oriana, ensuring strategies relating to finance, accounting, legal and fundraising are executed in a timely manner. On a daily basis, Alex ensures AOA's operations are running smoothly and efficiently.
Alex has a degree and MSc from the University of Southampton and University College London.
CDO & Co-Founder
Anna is a dynamic business leader with a passion for advancing healthcare through world-class diagnostics.
Most recently Anna led multiple business development teams for companies focused on novel diagnostic devices including maternal fetal medicine and inflammatory autoimmune diseases, encompassing product development, clinical development, economic modeling, marketing and launch.
Anna has overseen the inclusion of multiple product into national and pan-European guidelines, and she has experience with US FDA submissions for 510(k), PMA, and CLIA LTD regulatory routes.
As Chief Development Officer, Anna has overall responsibility for fulfilling AOA's scientific mission, product development and building shareholder value.
Anna holds a degree in International Finance and Business Administration from Boston University Questrom School of Management.
Prasad Gawande PhD
Vice President R&D
Prasad is a visionary leader and a technical expert. He is a proven executive with a successful track record of translating several bench top technologies into validated biomarker panels for regulatory submissions - LDT, 510k, PMA - in oncology, neurology, hematology, and clinical chemistry domain. More recently, as an R&D Director and PI, Prasad led the successful FDA PMA submission for a novel prostate cancer diagnostic test, which also received Breakthrough Device Designation in 2019.
As a Vice President for R&D, Prasad is responsible for AOA’s product lifecycle from research to commercialization, currently leading the development, validation, and eventual FDA submission for the ovarian cancer diagnostic test. Prasad works on developing proprietary technology for monoclonal antibodies and immunoassays development for various diagnostic and therapeutic targets, system integration and IP analysis.
Prasad has completed B.Tech. in Chemical Engineering from ICT Mumbai and Ph.D. in Biological Chemistry-Biotechnology from University of California-Davis USA. Prasad has worked in world renowned global organizations, such as Fred Hutchinson Cancer Research Center, UC Davis Medical Center, Genentech, Novartis, National Chemical Laboratory-India, and IIT Bombay-India.
Professor Uri Saragovi, PhD
Chief Scientific Officer
Dr. Saragovi is a passionate and world-leading scientist in the area of Translational Medicine.
Dr. Saragovi has published over 200 publications and 21 patents, primarily focusing translational medicine. More recently Dr. Saragovi has focused on the targeting of gangliosides, which are used clinically for cancer diagnosis, prognosis, and therapy.
Dr. Saragovi based at McGill University and Lady Davis Institute at the Jewish General Hospital, Montreal.
Independent Board Member
Surbhi Sarna is the founder and former CEO of nVision medical, a medical device company that, to date, is the only device cleared by the FDA to collect cells from the fallopian tube for the detection of ovarian cancer. Having led the company from inception, nVision Medical was acquired by Boston Scientific in 2018 for $275m.
Most recently Surbhi became Y Combinator’s first-ever partner for healthcare and biotech, and she currently sits on the board of Penumbra, Progenity, Astia, Draper University and the Harker School. Surbhi has extensive experience with early product development, funding, clinical trials and commercialization.
Chief Financial Officer
Mr. Marchio brings 40+ years of experience in the biomedical and life science industries as a CFO.
Bert is an Entrepreneurial Financial Executive who has led finance functions for early stage, private equity sponsored, and international NYSE listed companies. His accomplishments include $82 million IPO and $56 million crossover financing, as well as raising over $40 million in Series A, B and C rounds of financing. Bert's experience extends to Finance Management, Investor Relations, Risk Management, Fund Raising, Tax Compliance and Mergers & Acquisitions.
Katrin Eurich, MD, MPH
Dr. Eurich is a current fellow in Gynecologic Oncology at Brown University and Rhode Island Hospital. Dr. Eurich completed her residency in Obstetrics and Gynecology at the University of Washington in Seattle. Her research focuses on improving the detection and treatment of gynecologic cancers, with particular interests in endometrial and ovarian cancer, and those women that have the BRCA mutation. Dr. Eurich has published and presented research at various meetings including the annual Society of Gynecologic Oncology meetings and the Western Association of Gynecologic Oncologists meetings.